Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Aoife Brennan
Aoife Brennan is recorded as CEO, CFO and Board Member at Climb Bio, Inc. (CLYM) and Board Member at Xilio Therapeutics, Inc. (XLO). Earlier roles on record: CEO and Board Member at Synlogic, Inc. (SYBX) until March 9, 2024. Climb Bio, Inc. reported in an 8-K filed May 23, 2025 that Aoife Brennan was appointed interim principal financial officer, effective May 24, 2025. Climb Bio, Inc. reported in an 8-K filed June 27, 2024 that Aoife Brennan was appointed Board of Directors. Climb Bio, Inc. reported in an 8-K filed June 27, 2024 that Aoife Brennan was appointed President and Chief Executive Officer. Equibles holds 7 filed executive changes naming Aoife Brennan; each is listed under recent activity with its source filing. The proxy statement of Climb Bio, Inc. reports total compensation of $2,922,223 for Aoife Brennan in fiscal 2025, including a base salary of $669,500. Disclosed compensation is on record for 2 fiscal years. Aoife Brennan has spoken on 10 earnings calls and 2 other investor events across 2 companies, most recently for Climb Bio, Inc. on September 16, 2026.
“On the Separation Date, the Board of Directors of the Company appointed Aoife Brennan as the Company’s interim principal financial officer, effective as of May 24, 2025.”
Climb Bio, Inc. Form 8-K, filed May 23, 2025
· Read the filing
“Dr. Aoife Brennan and Dr. Stephen Thomas will also join Eliem's Board of Directors.”
Climb Bio, Inc. Form 8-K, filed June 27, 2024
· Read the filing
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
